AMGEN Inc.
AMGN
Market Cap$156.51B
Close$
Earnings Call Q4 2024
February 4, 2025 - AI Summary
Strong Revenue Growth: Amgen reported full-year total revenues of $33.4 billion, growing 19% year-over-year, driven by strong performance from 21 products achieving record sales. Product sales also increased 19%, largely fueled by a 23% increase in volume across their portfolio, indicating robust demand for their medicines.
Product Highlights and Forecast: Key growth drivers such as Repatha and EVENITY, which delivered 36% and 35% growth in sales respectively, are expected to continue driving revenues in 2025. The expectations for 2025 total revenues are forecasted to be in the range of $34.3 billion to $35.7 billion, reflecting a steady growth trajectory amid numerous opportunities across therapeutic areas.
Investment in R&D and Innovation: Non-GAAP R&D spending increased by 25% year-over-year to $5.9 billion, focusing on advancing late-stage pipeline products like MariTide and olpasiran. The commitment to innovation is evident, with expectations for ongoing R&D investment, supported by advances in technology and AI, which are anticipated to streamline development processes.
Exclusive for Stockcircle Pro members
Sign up
$718.84
145.5% upside
Current Fair Value
145.5% upsideUndervalued by 145.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $156.51 Billion |
|---|---|
| Enterprise Value | $204.63 Billion |
| Dividend Yield | $9.52 (3.90850391537299%) |
| Earnings per Share | $7.56 |
| Beta | 0.56 |
| Outstanding Shares | 537,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 38.23 |
|---|---|
| PEG | -209.44 |
| Price to Sales | 4.72 |
| Price to Book Ratio | 29.28 |
| Enterprise Value to Revenue | 6.14 |
| Enterprise Value to EBIT | 28.61 |
| Enterprise Value to Net Income | 50 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 10.23 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AMGEN Inc.
22,000 employees
CEO: Robert Bradway Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advan...